Laser therapy for retinopathy in sickle cell disease

Area of Science:

• Ophthalmology
• Hematology
• Medical Interventions

Background:

• Sickle cell disease (SCD) can cause ocular complications, notably proliferative sickle retinopathy (PSR), characterized by new blood vessel growth.
• Vision-threatening complications in PSR necessitate effective treatment strategies to prevent sight loss.

Purpose of the Study:

• To evaluate the effectiveness and safety of various laser photocoagulation techniques for treating proliferative sickle retinopathy (PSR) in individuals with sickle cell disease (SCD).

Main Methods:

• Systematic review of randomized controlled trials comparing laser photocoagulation to no treatment in patients with SCD-related PSR.
• Searched multiple databases including Cochrane Haemoglobinopathies Trials Register, LILACS, ICTRP, and ClinicalTrials.gov.
• Three trials involving 414 eyes of 339 participants were included, with data analyzed narratively due to heterogeneity.

Main Results:

• Evidence for laser photocoagulation's efficacy in PSR regression and preventing new occurrences was of very low certainty.
• Some trials suggested potential benefits in reducing visual loss and vitreous hemorrhage, but results were often not statistically significant or based on limited data.
• Adverse effects like retinal tears were rare; one trial noted a higher risk of choroidal neovascularization with xenon arc treatment.

Conclusions:

• The current evidence, derived from three trials (two over 30 years old) of low to very low certainty, is insufficient to confirm the effectiveness of laser photocoagulation for PSR.
• Uncertainty remains regarding laser therapy's impact on clinical outcomes and patient-important factors like quality of life.
• Further research is recommended to compare laser treatment with newer interventions (e.g., anti-VEGF) and evaluate cost-effectiveness.